2007
Role of APOBEC3G/F-Mediated Hypermutation in the Control of Human Immunodeficiency Virus Type 1 in Elite Suppressors
Gandhi S, Siliciano J, Bailey J, Siliciano R, Blankson J. Role of APOBEC3G/F-Mediated Hypermutation in the Control of Human Immunodeficiency Virus Type 1 in Elite Suppressors. Journal Of Virology 2007, 82: 3125-3130. PMID: 18077705, PMCID: PMC2259015, DOI: 10.1128/jvi.01533-07.Peer-Reviewed Original ResearchConceptsElite suppressorsAntiretroviral therapyHuman immunodeficiency virus type 1 (HIV-1) replicationHIV-1-infected individualsHuman immunodeficiency virus type 1Immunodeficiency virus type 1Control of viremiaActive antiretroviral therapyType 1 replicationVirus type 1Host defense mechanismsViral loadCopies/Clinical significanceAPOBEC3 activityType 1APOBEC3 familyViremiaPatientsTherapyProviral genomeCytidine deaminasesF proteinDefense mechanismsNovel assay
2004
Non‐redundancy of cytidine deaminases in class switch recombination
Fugmann SD, Rush JS, Schatz DG. Non‐redundancy of cytidine deaminases in class switch recombination. European Journal Of Immunology 2004, 34: 844-849. PMID: 14991614, DOI: 10.1002/eji.200324418.Peer-Reviewed Original ResearchConceptsActivation-induced cytidine deaminaseClass switch recombinationAPOBEC-1Human activation-induced cytidine deaminaseSwitch recombinationCognate substratesCatalytic mutantGene conversionClose homologueProkaryotic cellsInactive mutantMurine B cellsDistinct mRNAsCytidine deaminase activityCytidine deaminasesImmunoglobulin genesDiversification mechanismsCytidine deaminaseSomatic hypermutationUnknown mechanismDeaminase activityMutantsPrecise roleActivated B cellsB cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply